tiprankstipranks
Trending News
More News >

Ascletis Pharma Secures FDA Clearance for Psoriasis Drug Trial

Story Highlights
Ascletis Pharma Secures FDA Clearance for Psoriasis Drug Trial

Confident Investing Starts Here:

The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).

Ascletis Pharma Inc. has announced that the U.S. FDA has cleared its IND application for ASC50, an oral small molecule IL-17 inhibitor, for a Phase I trial targeting mild-to-moderate plaque psoriasis. ASC50 has shown promising preclinical results, including higher drug exposure and strong efficacy, positioning it as a potential best-in-class treatment. The Phase I trial is set to begin in the third quarter of 2025, marking a significant step in Ascletis’s development pipeline.

The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on discovering and developing innovative drugs for the treatment of autoimmune and inflammatory diseases. The company specializes in oral small molecule inhibitors, with a market focus on conditions such as psoriasis.

Average Trading Volume: 7,167,514

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.11B

Learn more about 1672 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1